Genzyme, Sanofi Mum On Merger Negotiations At JPM Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme depicts itself as the picture of health with enzyme replacement therapy business returning to normal after manufacturing woes.
You may also be interested in...
Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business
Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.
Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business
Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.
Sanofi And Genzyme Move Closer To A Deal
Companies enter confidentiality agreement allowing Sanofi to conduct due diligence and reportedly have agreed on outlines of a deal.